Discrimination of ischemic and hemorrhagic strokes using a multiplexed, mass spectrometry‐based assay for serum apolipoproteins coupled to multi‐marker <scp>ROC</scp> algorithm

Lopez, Mary F.; Sarracino, David; Prakash, Amol; Athanas, Michael; Krastins, Bryan; Rezai, Taha; Sutton, Jennifer N.; Peterman, Scott; Gvozdyak, Oksana; Chou, Sherry; Lo, Eng H.; Buonanno, Ferdinand; Ning, MingMing

doi:10.1002/prca.201100041

Cited by 34 publications

(35 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The application of multiple biomarkers could help elucidate the complex interactions among different organs and systems during and after cardiac arrest10. The combination of markers from different physiological systems can improve risk stratification in diseases such as sudden cardiac death, sepsis, and cerebral vascular insults192021.…”

Section: Discussionmentioning

confidence: 99%

Predicting the outcomes for out-of-hospital cardiac arrest patients using multiple biomarkers and suspension microarray assays

Tsai

Chien

Chang

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Predicting the prognosis for cardiac arrest is still challenging. Combining biomarkers from diverse pathophysiological pathways may provide reliable indicators for the severity of injury and predictors of long-term outcomes. We investigated the feasibility of using a multimarker strategy with key independent biomarkers to improve the prediction of outcomes in cardiac arrest. Adult out-of-hospital cardiac arrest patients with sustained return of spontaneous circulation were prospectively enrolled in this study. Blood samples were taken at 2 and 24 hours after cardiac arrest. Suspension microarray assays were used to test 21 different biomarkers. A total of 99 patients were enrolled, 45 of whom survived to hospital discharge. We identified 11 biomarkers that, when combined with clinical variables and factors of APACHE II score and history of arrhythmia, were independent determinants for outcome of in-hospital mortality (concordance = 0.9249, standard error = 0.0779). Three biomarkers combined with APACHE II and age were independent determinants for favorable neurological outcome at hospital discharge (area under the receiver-operator characteristic curve, 0.938; 95% confidence interval, 0.854 ~ 1.0). In conclusion, a systemic multiple biomarker approach using suspension microarray assays can identify independent predictors and model the outcomes of cardiac arrest patients during the postcardiac arrest period.

show abstract

Section: Discussionmentioning

confidence: 99%

Predicting the outcomes for out-of-hospital cardiac arrest patients using multiple biomarkers and suspension microarray assays

Tsai

Chien

Chang

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Conversely, samples enriched at the protein level are digested after capture and are therefore far less complex. In this case, trypsin digestion is typically fast (2–4 h), more economical and highly reproducible ([13,37,55], this paper). Finally, there is the problem of quantification of non-unique peptides with anti-peptide antibodies.…”

Section: Discussionmentioning

confidence: 99%

“…In some cases, other proteolytic enzymes such as SV8 (Thermo Fisher Scientific) were used to generate peptides with the desired target sequences. Previous experiments using a concatenated, heavy isotope-labeled synthetic concatenated peptide standard demonstrated consistent tryptic digestion with an average digestion efficiency of 64% [55]. …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum

Krastins

Prakash

Sarracino

et al. 2013

Clinical Biochemistry

Self Cite

View full text Add to dashboard Cite

Objectives The aim of this study was to develop high-throughput, quantitative and highly selective mass spectrometric, targeted immunoassays for clinically important proteins in human plasma or serum. Design and methods The described method coupled mass spectrometric immunoassay (MSIA), a previously developed technique for immunoenrichment on a monolithic microcolumn activated with an anti-protein antibody and fixed in a pipette tip, to selected reaction monitoring (SRM) detection and accurate quantification of targeted peptides, including clinically relevant sequence or truncated variants. Results In this report, we demonstrate the rapid development of MSIA-SRM assays for sixteen different target proteins spanning seven different clinically important areas (including neurological, Alzheimer's, cardiovascular, endocrine function, cancer and other diseases) and ranging in concentration from pg/mL to mg/mL. The reported MSIA-SRM assays demonstrated high sensitivity (within published clinical ranges), precision, robustness and high-throughput as well as specific detection of clinically relevant isoforms for many of the target proteins. Most of the assays were tested with bona-fide clinical samples. In addition, positive correlations, (R2 0.67–0.87, depending on the target peptide), were demonstrated for MSIA-SRM assay data with clinical analyzer measurements of parathyroid hormone (PTH) and insulin growth factor 1 (IGF1) in clinical sample cohorts. Conclusions We have presented a practical and scalable method for rapid development and deployment of MS-based SRM assays for clinically relevant proteins and measured levels of the target analytes in bona fide clinical samples. The method permits the specific quantification of individual protein isoforms and addresses the difficult problem of protein heterogeneity in clinical proteomics applications.

show abstract

“…In a recent study, Lopez et al (2012) used a reaction monitoring assay to a panel of nine apolipoproteins. They found that the plasma levels of specific apolipoproteins, including apo C-I and apo C-III, distinguished (with high sensitivity and specificity) IS, HS, and normal patient sample groups from each other [56]. …”

Section: Protein Biomarkers In Ischemic Strokementioning

confidence: 99%

Peripheral biomarkers of stroke: Focus on circulatory microRNAs

Vijayan

Reddy

2016

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

102

View full text Add to dashboard Cite

Stroke is the second leading cause of death in the world. Stroke occurs when blood flow stops, and that stoppage results in reduced oxygen supply to neurons in the brain. The occurrence of stroke increases with age, but anyone at any age can suffer from stroke. Recent research has implicated multiple cellular changes in stroke patients, including oxidative stress and mitochondrial dysfunction, inflammatory responses, and changes in mRNA and proteins. Recent research has also revealed that stroke is associated with modifiable and non-modifiable risk factors. Stroke can be controlled by modifiable risk factors, including diet, cardiovascular, hypertension, smoking, diabetes, obesity, metabolic syndrome, depression and traumatic brain injury. Stroke is the major risk factor for vascular dementia (VaD) and Alzheimer’s disease (AD). The purpose of this article is to review the latest developments in research efforts directed at identifying 1) latest developments in identifying biomarkers in peripheral and central nervous system tissues, 2) changes in microRNAs (miRNAs) in patients with stroke, 3) miRNA profile and function in animal brain, and 4) protein biomarkers in ischemic stroke. This article also reviews research investigating circulatory miRNAs as peripheral biomarkers of stroke.

show abstract

Discrimination of ischemic and hemorrhagic strokes using a multiplexed, mass spectrometry‐based assay for serum apolipoproteins coupled to multi‐marker ROC algorithm

Cited by 34 publications

References 38 publications

Predicting the outcomes for out-of-hospital cardiac arrest patients using multiple biomarkers and suspension microarray assays

Predicting the outcomes for out-of-hospital cardiac arrest patients using multiple biomarkers and suspension microarray assays

Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum

Peripheral biomarkers of stroke: Focus on circulatory microRNAs

Contact Info

Product

Resources

About